source
- Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potentialMerck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led analysts to predict “limited competitive potential” in diabetic macular ede…
- Japan's PMDA Issues Guidance to Safeguard Participants in Generic Bioequivalence TrialsThe Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has released new guidance aimed at protecting healthy adult volunteers who take part in generic bioequivalence studies. The document…